Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 82107 refers to a laboratory test that quantifies the levels of alpha-fetoprotein (AFP) and its specific isoform, the AFP-L3 fraction. This test is particularly significant in the context of liver health, as it serves as a biomarker for hepatocellular carcinoma, a type of liver cancer. The measurement involves assessing both the total AFP and the AFP-L3 fraction, with results expressed as a ratio. The AFP-L3 fraction is notable for its association with aggressive tumor behavior, including rapid growth and early metastasis, making it a critical marker in evaluating the progression of liver cancer. The test utilizes a liquid phase binding immunoassay to isolate the AFP-L3 isoform, followed by quantification through chemical luminescence techniques. The resulting AFP-L3% ratio, which compares the amount of AFP-L3 to the total AFP, is essential for monitoring patients with chronic liver disease who are at high risk for developing hepatocellular carcinoma. A ratio exceeding 10% is particularly concerning and may indicate the presence of early-stage liver cancer, thus highlighting the importance of this test in clinical practice.
© Copyright 2026 Coding Ahead. All rights reserved.
The test coded by CPT® 82107 is indicated for the following conditions:
The procedure for conducting the test associated with CPT® 82107 involves several key steps:
After the procedure, the patient may experience minimal discomfort at the venipuncture site, but no specific post-procedure care is typically required. The results of the AFP and AFP-L3 fraction test are usually available within a few days, and healthcare providers will interpret the results in the context of the patient's overall clinical picture. If the AFP-L3% ratio is found to be greater than 10%, further diagnostic evaluation may be warranted to assess for the presence of hepatocellular carcinoma or to monitor disease progression in high-risk patients.
| Short Descr | ALPHA-FETOPROTEIN L3 | Medium Descr | AFP-L3 FRACTION ISOFORM & TOTAL AFP W/RATIO | Long Descr | Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | 77 | Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | GZ | Item or service expected to be denied as not reasonable and necessary |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Medium description changed. |
| 2007-01-01 | Added | First appearance in code book in 2007. |
Get instant expert-level medical coding assistance.